ISPOR Publishes New Global Healthcare Systems Road Map- Egypt Pharmaceuticals

Published Oct 1, 2018

New “Road Map” Reports on Egypt’s Universal Healthcare Coverage Goals

Lawrenceville, NJ, USA—October 1, 2018—ISPOR, the professional society for health economics and outcomes research (HEOR), announced that it has published a new Global Healthcare Systems Road Map—Egypt Pharmaceuticals. ISPOR Global Healthcare Systems Road Maps provide an overview of country-specific, healthcare delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of 3 segments—pharmaceutical, medical devices, or diagnostics. The Society’s “Road Maps” can benefit a variety of stakeholders—such as healthcare decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for healthcare technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific healthcare experts and are updated over time to reflect changes in the country’s healthcare delivery system. With 100 million citizens, the Arab Republic of Egypt is the most populous country in the Arab world and the third most populous in Africa, according to the 2017 census. Egypt has one of the largest healthcare markets in the Middle East and North Africa. The newly published ISPOR Global Healthcare Systems Road Map—Egypt Pharmaceuticals, reports that universal healthcare coverage, a sustainable development goals for 2030 in the country, will be implemented in stages. The first phase will start in late 2018 and will cover the population of 5 governorates in Egypt—Port Said, Suez, Ismailia, North Sinai, and South Sinai. Coverage will gradually expand to include the entire population by 2032. Currently, approximately 43% of Egypt’s population is without health insurance coverage. In their 2016/2017 fiscal year budget, Egypt allocated 53.3 billion Egyptian pounds to healthcare spending, which represents 5.7% of total government spending, or 1.6% of gross domestic product (GDP), far below the recommended 3% of GDP as per the Constitution. The World Health Organization’s data on current health expenditure (CHE) as percentage of GDP indicated that CHE was 4.2% of GDP in 2015. The Global Healthcare Systems Road Map—Egypt Pharmaceuticals is freely available here. Additional information on Egypt can be found in ISPOR’s Pharmacoeconomic Guidelines Around the World—Egypt. Additional information on universal healthcare can be found in ISPOR’s 2018 Top 10 HEOR Trends report. All of the Society’s HEOR tools and resources can be found here.

###

ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×